STOCK TITAN
  1. Home
  2. News
  3. VRTX

Vertex Pharmaceuticals Inc - VRTX STOCK NEWS

Welcome to our dedicated page for Vertex Pharmaceuticals news (Ticker: VRTX), a resource for investors and traders seeking the latest updates and insights on Vertex Pharmaceuticals stock.

Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) is a leading American biopharmaceutical company headquartered in Boston, Massachusetts. The company is renowned for its pioneering approach to drug discovery and development. Vertex was one of the first biotech firms to adopt rational drug design, a strategy that focuses on understanding the biological mechanisms of diseases to create targeted therapies, rather than relying on combinatorial chemistry.

Vertex's Core Business: Vertex specializes in the discovery and development of small-molecule drugs aimed at treating serious diseases. The company has made significant strides in the treatment of cystic fibrosis (CF) with its portfolio of medications including Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, which have set the standard of care for CF patients worldwide.

Diversification and Innovation: Vertex is not limited to CF treatments. The company has recently expanded its pipeline with Casgevy, a groundbreaking gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is developing nonopioid small-molecule inhibitors to target acute and chronic pain and small-molecule inhibitors for APOL1-mediated kidney diseases. The company is also exploring cell therapies that offer potential functional cures for type 1 diabetes (T1D).

Recent Achievements: Vertex has entered into a notable partnership with TreeFrog Therapeutics to utilize TreeFrog's proprietary cell manufacturing technology, C-Stem™, to optimize the production of Vertex's cell therapies for T1D. This collaboration aims to scale up stem cell production, potentially transforming T1D treatment by providing large quantities of fully differentiated cells.

Financial Condition and Partnerships: Vertex continues to maintain a strong financial position, enabling it to fund extensive research and development projects. Under the agreement with TreeFrog, Vertex will make an upfront payment of $25M and an equity investment, with up to $215M in milestones and additional potential payments of $540M in clinical, regulatory, and commercial milestones. Vertex will cover all R&D costs associated with this partnership.

In summary, Vertex Pharmaceuticals Inc. is a trailblazing biopharmaceutical company committed to transforming lives through innovative therapies for serious diseases. Its extensive portfolio, strategic partnerships, and robust pipeline make it a key player in the biotechnology sector.

News

Vertex to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8

Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) CEO to Present at J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
conferences
-
News

Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the conditional approval of CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) for patients 12 years of age and older. If approved, exa-cel would be the only genetic therapy for eligible patients in the European Union. An approval decision by the European Commission is expected in Q1 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
none
-
News

Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy

Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced positive results from its Phase 2 study of the NaV1.8 inhibitor VX-548 in treating painful diabetic peripheral neuropathy. The study showed statistically significant and clinically meaningful reduction in pain intensity, with VX-548 being generally well tolerated. Vertex plans to advance VX-548 into pivotal development for diabetic peripheral neuropathic pain and has also initiated a Phase 2 study in patients with painful lumbosacral radiculopathy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.23%
Tags
clinical trial
News

Positive Results from Pivotal Trials of CASGEVY™ (exagamglogene autotemcel) Highlighted in Oral Presentations at the American Society of Hematology (ASH) Annual Meeting and Exposition

Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) presents data at ASH Annual Meeting demonstrating consistent and durable response to treatment with CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
none
-
News

Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease

Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (VRTX) and CRISPR Therapeutics (CRSP) announced the FDA approval of CASGEVY™, a CRISPR-based gene-editing therapy, for the treatment of sickle cell disease in patients 12 years and older. This marks the first-ever approval of a CRISPR-based gene-editing therapy in the U.S. and offers a one-time treatment option for approximately 16,000 eligible patients with severe sickle cell disease. The therapy has the potential to eliminate severe vaso-occlusive crises and hospitalizations caused by the disease, providing a functional cure for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.08%
Tags
fda approval
-
News

Vertex Appoints Nancy Thornberry to its Board of Directors

Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) appoints Nancy Thornberry, a veteran in the pharmaceutical and biotech industries, to its Board of Directors. With over 35 years of experience and a remarkable track record, her addition is expected to bring great value to the company as it continues to expand and progress its pipeline of novel and innovative therapies for serious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
management
News

Vertex Announces European Medicines Agency Validation for Marketing Authorization Application Extension for KAFTRIO® in Combination With Ivacaftor to Include People With Cystic Fibrosis and Responsive Rare Mutations

Rhea-AI Summary
Vertex Pharmaceuticals (VRTX) has applied to expand the approved indication for KAFTRIO® in combination with ivacaftor for the treatment of people with cystic fibrosis (CF) ages 2 and above who have a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive based on clinical and/or in vitro data, including the N1303K mutation. If approved, ~2,800 people with CF in the European Union could receive a medicine that treats the underlying cause of their disease for the first time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
none
-
News

European Commission Approves KAFTRIO® in Combination With Ivacaftor for the Treatment of Children With Cystic Fibrosis Ages 2 Through 5

Rhea-AI Summary
Vertex Pharmaceuticals (VRTX) receives European Commission approval for label expansion of KAFTRIO for children ages 2 through 5 years old with cystic fibrosis, potentially treating the underlying cause of the disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Rhea-AI Summary
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) announced the first regulatory authorization of a CRISPR-based gene-editing therapy in the world. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for CASGEVY, a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The therapy is indicated for eligible patients 12 years of age and older. CASGEVY has been authorized for the treatment of patients with recurrent vaso-occlusive crises or TDT, for whom a human leukocyte antigen (HLA) matched related hematopoietic stem cell donor is not available. The safety profile of patients treated with CASGEVY in clinical trials is generally consistent with myeloablative conditioning with busulfan and hematopoietic stem cell transplant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.32%
Tags
none
News

Vertex Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Vertex Pharmaceuticals reported Q3 2023 product revenue of $2.48 billion, a 6% increase compared to Q3 2022. The company raised its full-year 2023 product revenue guidance to approximately $9.85 billion. The U.S. FDA Advisory Committee meeting for exa-cel in SCD is completed, with a PDUFA date set for December 8, 2023. The pipeline is advancing with Phase 3 data in CF and acute pain expected in early 2024, and Phase 2 data in neuropathic pain expected in late 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.95%
Tags
earnings

FAQ

What is the current stock price of Vertex Pharmaceuticals (VRTX)?

The current stock price of Vertex Pharmaceuticals (VRTX) is $465.7 as of November 15, 2024.

What is the market cap of Vertex Pharmaceuticals (VRTX)?

The market cap of Vertex Pharmaceuticals (VRTX) is approximately 118.3B.

What does Vertex Pharmaceuticals specialize in?

Vertex Pharmaceuticals specializes in discovering and developing small-molecule drugs for serious diseases, with a notable focus on cystic fibrosis.

What are Vertex's key drugs for cystic fibrosis?

Vertex's key drugs for cystic fibrosis include Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio.

What recent partnerships has Vertex entered into?

Vertex has recently partnered with TreeFrog Therapeutics to utilize their C-Stem™ technology for optimizing cell therapies for type 1 diabetes (T1D).

What is the significance of Vertex's partnership with TreeFrog Therapeutics?

The partnership aims to improve the production of fully differentiated cells for T1D treatments, potentially transforming T1D care.

What financial commitments has Vertex made in its collaboration with TreeFrog?

Vertex has committed to a $25M upfront payment, an equity investment, and up to $215M in milestones, with additional potential payments of $540M in clinical, regulatory, and commercial milestones.

Does Vertex focus solely on cystic fibrosis treatments?

No, Vertex is also developing therapies for beta thalassemia, sickle-cell disease, acute and chronic pain, APOL1-mediated kidney diseases, and type 1 diabetes.

What is the C-Stem™ technology?

C-Stem™ is a cell manufacturing technology by TreeFrog that mimics the natural microenvironment, allowing cells to grow exponentially in 3D, which is being used to enhance Vertex's T1D therapies.

What is rational drug design?

Rational drug design is a strategy that involves understanding the biological mechanisms of diseases to create targeted therapies, as opposed to combinatorial chemistry.

Where is Vertex Pharmaceuticals headquartered?

Vertex Pharmaceuticals is headquartered in Boston, Massachusetts.

How can I get more information about Vertex Pharmaceuticals?

You can visit Vertex's official website at www.vrtx.com or follow them on LinkedIn, Facebook, Instagram, YouTube, and Twitter/X for the latest updates.

Stock VRTX logo
Vertex Pharmaceuticals Inc

Nasdaq:VRTX

VRTX Rankings

#105 Ranked by Market Cap
N/A Ranked by Dividends

VRTX Stock Data

118.29B
257.53M
0.09%
95.96%
1.66%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOSTON